Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments | Zendy

Matthias Naegele | Zendy; Andreas J. Flammer | Zendy; Frank Enseleit | Zendy; Frank Ruschitzka | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments

Author(s) -

Matthias Naegele,

Andreas J. Flammer,

Frank Enseleit,

Frank Ruschitzka

Publication year - 2016

Publication title -

schweizerische medizinische wochenschrift

Language(s) - English

Resource type - Journals

ISSN - 0036-7672

DOI - 10.4414/smw.2016.14295

Subject(s) - medicine , ejection fraction , heart failure , neprilysin , blockade , intensive care medicine , disease , angiotensin receptor blockers , cardiology , pharmacotherapy , medical therapy , renin–angiotensin system , receptor , blood pressure , biochemistry , chemistry , enzyme

Heart failure with reduced ejection fraction (HFrEF) is a common cardiovascular condition with a significant individual and societal burden. Although it was previously known as a palliative condition, medical drug therapies that were developed in the last four decades significantly reduced morbidity and mortality of the disease. The cornerstone of HFrEF therapy remains the blockade of the renin-angiotensin-aldosterone and the β-adrenergic systems. This review aims to give an overview and update on established disease-modifying therapies in HFrEF, discuss advances and setbacks in the treatment of selected comorbidities and provide an outlook on upcoming therapies including the new concept of dual angiotensin receptor and neprilysin inhibition

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research